Objective To investigate the expression levels of vascular endothelial growth factor A(VEGFA) and small ubiquitin associated modifier specific proteinase 5(SENP5) in prostate cancer, and their clinical significance.
Methods The GEPIA database was used to analyze the correlation between VEGFA, SENP5 genes and survival of prostate cancer patients. The qRT-PCR and Western blotting were used to detect the mRNA and protein expression levels of VEGFA and SENP5 in cancer cells. The tissue samples and clinical data of prostate cancer patients were collected, and the protein expressions of VEGFA and SENP5 in prostate cancer tissues were detected by immunohistochemical method, and the relationship between their expression levels and clinicopathological parameters of cancer patients were analyzed. The VEGFA and SENP5 protein interaction network map was constructed by using STRING website.
Results The VEGFA was correlated with the overall survival of prostate cancer patients(P < 0.05), and the SENP5 was correlated with overall survival and progression-free survival of patients(P < 0.05). Compared with the normal cells, the mRNA and protein of VEGFA and SENP5 were highly expressed in prostate cancer cells(P < 0.05). Light yellow or brown yellow staining of VEGFA and SENP5 protein could be seen in tumor pathological tissues. VEGFA was mainly expressed in cytoplasm, while SENP5 was mainly expressed in nucleus. The strong positive expression of VEGFA was correlated with the clinical stage and presence or absence of distant metastasis(P < 0.05), and the strong positive expression of SENP5 was correlated with the Gleason score and presence or absence of distant metastasis(P < 0.05). There was significant correlation between VEGFA and SENP5(P < 0.01). SENP5 might interact with VEGFA via the SUMO1-HSP90AA1 axis.
Conclusions VEGFA and SENP5 are highly expressed in prostate cancer, and related to tumor clinicopathological parameters, which may be potential therapeutic targets for prostate cancer patients.
DownLoad: